resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. Strong scientific evidence suggests that aging is regulated by specific biochemical pathways. Medicines that target these biochemical pathways, such as the TORC1 pathway, may prevent or treat a variety of aging related diseases. resTORbioâs lead clinical program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including immune, neurologic and cardiac function. Inhibition of TORC1 has the potential to improve the function of aging organ systems and address multiple aging related diseases. Source
No articles found.
Cidara is a clinical-stage biotechnology company focused on the discovery, develop...
Cidara is a clinical-stage biotechnology compan...
Amgen is committed to unlocking the potential of biology for patients suffering fr...
Amgen is committed to unlocking the potential o...
Magellan Health, Inc., a Fortune 500 company, is a leader in managing the fastest ...
Magellan Health, Inc., a Fortune 500 company, i...
We are a clinical stage, publicly traded specialty pharmaceutical company, focused...
We are a clinical stage, publicly traded specia...
Join the National Investor Network and get the latest information with your interests in mind.